Business
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaignAdditional clinical sites in ongoing babesiosis treatment trials will be initiated in light of FDA feedback regarding Company’s breakthrough therapy designation request WASHINGTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Comp
About this update from 60 Degrees Pharmaceuticals, Inc.
[{"type":"image","alt":"Sixty Degrees Pharmaceuticals","displaySize":"","headline":null,"caption":"Sixty Degrees Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L1lrb.zKykt_bMbAkYncaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"6-month commercial pilot demonstrated increasing demand among prescribers","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"Expansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaign","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional clinical sites in ongoing babesiosis treatment trials will be initiated in light of FDA feedback regarding Company’s breakthrough therapy designation request","length":168,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":365,"olType":false},{"type":"text","content":"WASHINGTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the planned expansion of the Company’s sales and marketing initiatives after encouraging results from a 6-month commercial pilot that showed an overall increase in product sales. The positive outcome points to increasing market demand for ARAKODA® among prescribers.","length":510,"tagName":"p"},{"type":"text","content":"In response to the encouraging results, the Company will implement several strategic initiatives designed to expand market reach and accelerate ARAKODA sales in 2026:","length":166,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Inside Sales Team Expansion:The number of inside sales representatives will increase to deepen outreach across prescribers, strengthen provider relationships, and enhance product education and support.","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"GoodRx Partnership for Broader Offer Visibility:The Company will engage with GoodR...